The stock price of Standard BioTools Inc (NASDAQ: LAB) has dropped by -1.76 compared to previous close of 1.19. Despite this, the company has seen a gain of 0.78% in its stock price over the last five trading days. globenewswire.com reported 2025-02-27 that SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) — Standard BioTools Inc. (NASDAQ: LAB) today announced that company management will participate in the following investor conferences:
Is It Worth Investing in Standard BioTools Inc (NASDAQ: LAB) Right Now?
The stock has a 36-month beta value of 1.52. Opinions on the stock are mixed, with 2 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for LAB is 366.94M, and at present, short sellers hold a 4.29% of that float. On March 27, 2025, the average trading volume of LAB was 1.94M shares.
LAB’s Market Performance
LAB stock saw a decrease of 0.78% in the past week, with a monthly decline of -0.09% and a quarterly a decrease of -37.49%. The volatility ratio for the week is 6.34%, and the volatility levels for the last 30 days are 8.42% for Standard BioTools Inc (LAB). The simple moving average for the last 20 days is 2.62% for LAB’s stock, with a simple moving average of -34.10% for the last 200 days.
Analysts’ Opinion of LAB
TD Cowen, on the other hand, stated in their research note that they expect to see LAB reach a price target of $3.50. The rating they have provided for LAB stocks is “Buy” according to the report published on April 16th, 2024.
Jefferies gave a rating of “Buy” to LAB, setting the target price at $3.25 in the report published on April 04th of the previous year.
LAB Trading at -13.37% from the 50-Day Moving Average
After a stumble in the market that brought LAB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -61.55% of loss for the given period.
Volatility was left at 8.42%, however, over the last 30 days, the volatility rate increased by 6.34%, as shares surge +11.96% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -41.79% lower at present.
During the last 5 trading sessions, LAB rose by +0.86%, which changed the moving average for the period of 200-days by -49.57% in comparison to the 20-day moving average, which settled at $1.1393. In addition, Standard BioTools Inc saw -33.20% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LAB starting from Casdin Partners Master Fund, L, who purchase 4,820,959 shares at the price of $1.06 back on Feb 28 ’25. After this action, Casdin Partners Master Fund, L now owns 58,846,780 shares of Standard BioTools Inc, valued at $5,134,321 using the latest closing price.
Black Jeffrey G., the Former Officer of Standard BioTools Inc, proposed sale 57,971 shares at $2.12 during a trade that took place back on Nov 12 ’24, which means that Black Jeffrey G. is holding shares at $123,098 based on the most recent closing price.
Stock Fundamentals for LAB
Current profitability levels for the company are sitting at:
- -1.0 for the present operating margin
- 0.48 for the gross margin
The net margin for Standard BioTools Inc stands at -0.8. The total capital return value is set at -0.32. Equity return is now at value -43.75, with -29.69 for asset returns.
Based on Standard BioTools Inc (LAB), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -4.35. The debt to equity ratio resting at 0.07. The interest coverage ratio of the stock is -52.85.
Currently, EBITDA for the company is -118.14 million with net debt to EBITDA at 1.05. When we switch over and look at the enterprise to sales, we see a ratio of 1.76. The receivables turnover for the company is 5.19for trailing twelve months and the total asset turnover is 0.28. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.70.
Conclusion
To sum up, Standard BioTools Inc (LAB) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
